Grizz Pharmaceutical

Grizzly Therapeutics is a private biotechnology company focused on the development of small molecule antiviral therapies. Founded by former Gilead Sciences executives, the company initially gained attention for its efforts to develop GC376, a 3C-like protease inhibitor, for the treatment of COVID-19. The company leverages deep expertise in virology and medicinal chemistry to target critical viral enzymes. While its primary focus has been on coronavirus treatments, its broader mission involves addressing unmet needs in infectious diseases. Grizzly Therapeutics operates largely in a stealth or early-stage capacity, focusing on optimizing its lead candidates for clinical entry.